rentiapril
- Product Name
- rentiapril
- CAS No.
- 72679-47-1
- Chemical Name
- rentiapril
- Synonyms
- SA-446 racemate;Rentiapril (racemate);2-(2'-Hydroxyphenyl)-3-(3-mercaptopropanoyl)-4-thiazolidine carboxylic acid;2-(2-hydroxyphenyl)-3-(3-sulfanylpropanoyl)-1,3-thiazolidine-4-carboxylic acid;4-Thiazolidinecarboxylic acid, 2-(2-hydroxyphenyl)-3-(3-mercapto-1-oxopropyl)-
- CBNumber
- CB51321949
- Molecular Formula
- C13H15NO4S2
- Formula Weight
- 313.39
- MOL File
- 72679-47-1.mol
rentiapril Property
- Boiling point:
- 553.7±50.0 °C(Predicted)
- Density
- 1.451±0.06 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- Soluble in DMSO
- form
- Solid
- pka
- 3.02±0.40(Predicted)
- color
- White to off-white
N-Bromosuccinimide Price
- Product number
- API0007327
- Product name
- RENTIAPRIL
- Purity
- 95.00%
- Packaging
- 5MG
- Price
- $497.77
- Updated
- 2021/12/16
rentiapril Chemical Properties,Usage,Production
Uses
Rentiapril racemate (SA-446 racemate) is the racemate of Rentiapril. Rentiapril is an angiotensin converting enzyme (ACE) inhibitor.
in vivo
A three-months toxicity study of an angiotensin converting enzyme (ACE) inhibitor, Rentiapril (CAS 80830-42-8), is performed in Sprague-Dawley rats by oral administration. The dose levels of 0, 30, 125, 500 and 1000 mg/kg are tested in both sexes, in which each experimental group comprised 10 rats. Another ACE inhibitor, captopril, is used as a reference compound. Rentiapril at the highest dose of 1000 mg/kg causes low food consumption and death of some animals with signs of bloody feces and anemia. In males and females receiving 500 and 1000 mg/kg, there are low body weight gain, increases in water intake, urine volume and serum BUN level, and decreases in levels of various erythrocytic parameters. Kidney weight is increased dose-dependently in both sexes. Histopathologically, renal changes in the 500 and 1000 mg/kg groups consist of proximal tubular degeneration, juxtaglomerular cell hyperplasia and interstitial cell infiltration. Similar, but mild, changes in proximal tubules are present in the female 125 mg/kg group. Dead animals from the highest dose groups further show gastrointestinal hemorrhagic erosion and/or ulcer, decrease bone marrow erythropoiesis and hepatocytic vacuolar degeneration. There is no pathological alteration in rats from other Rentiapril-treated groups, as well as in controls. These results indicate that the no-effect dose of Rentiapril in rats by three months oral administration is 30 mg/kg in female and 125 mg/kg in male[1].
References
[1] Takase K, et al. Toxicity study of the angiotensin converting enzyme inhibitor rentiapril in rats. Arzneimittelforschung. 1995 Jan;45(1):15-8. PMID:7893262
rentiapril Preparation Products And Raw materials
Raw materials
Preparation Products
rentiapril Suppliers
- Tel
- 1-(800)-881-8210
- Fax
- 615-250-9817
- inquiries@lgmpharma.com
- Country
- United States
- ProdList
- 2123
- Advantage
- 70
- Tel
- 021-58955995
- Fax
- 609-228-5909
- sales@medchemexpress.cn
- Country
- United States
- ProdList
- 4861
- Advantage
- 58
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Country
- United States
- ProdList
- 32435
- Advantage
- 58
- Tel
- --
- Fax
- --
- sales@medchemexpress.com
- Country
- United States
- ProdList
- 6398
- Advantage
- 58